Ranbaxy Laboratories inks licensing pact with Gilead Sciences

12 Jul 2011 Evaluate

Ranbaxy Laboratories, country’s largest drug maker has entered into a licensing agreement with Gilead Sciences to manufacture and market three new HIV/AIDS drugs which are currently in late stage clinical development. Ranbaxy will have the rights to produce and sell generic version of these drugs, under license, in India and other developing nations, after gaining necessary regulatory approvals.

As per the agreement, Ranbaxy will extend its existing relationship with Gilead for anti-retrovirals and have the right to manufacture and market generic equivalent of new products, Elvitegravir, an investigational integrase inhibitor, Cobicistant, an investigational antiretroviral boosting agent and Quad, which combines four Gilead HIV medicines in a ince-daily, single-tablet regimen.

The company posted a net loss from ordinary activities after tax of Rs 52.91 crore for the quarter ended March 31, 2011 as compared to net profit from ordinary activities after tax of Rs 871.80 crore for the corresponding quarter last year. Its total income decreased by 43.25% to Rs 1176.42 crore for the quarter under review from Rs 2073.06 crore in the corresponding previous quarter.

Peers
Company Name CMP
Sun Pharma Inds. 1786.85
Dr. Reddys Lab 1173.55
Cipla 1525.50
Lupin 2018.35
Zydus Lifesciences 859.10
View more..
© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.
×
Please wait your portfolio is updating...